Iron replacement therapy in heart failure: a literature review

Hassan Ismahel* and Nadeen Ismahel

Abstract

Background: Heart failure (HF) is a major global challenge, emphasised by its designation as the leading cause of hospitalisation in those aged 65 and above. Approximately half of all patients with HF have concurrent iron deficiency (ID) regardless of anaemia status. In HF, iron deficiency is independently associated with higher rates of hospitalisation and death, lower exercise capacity, and poorer quality-of-life than in patients without iron deficiency. With such consequences, several studies have investigated whether correcting ID can improve HF outcomes.

Main body.

As of 1st June 2021, seven randomised controlled trials have explored the use of intravenous (IV) iron in patients with HF and ID, along with various meta-analyses including an individual patient data meta-analysis, all of which are discussed in this review. IV iron was well tolerated, with a comparable frequency of adverse events to placebo. In the context of heart failure with reduced ejection fraction (HFrEF), IV iron reduces the risk of hospitalisation for HF, and improves New York Heart Association (NYHA) functional class, quality-of-life, and exercise capacity (as measured by 6-min walk test (6MWT)) distance and peak oxygen consumption. However, the effect of IV iron on mortality is uncertain. Finally, the evidence for IV iron in patients with acute decompensated heart failure, or heart failure with preserved ejection fraction (HFpEF) is limited.

Conclusions: IV iron improves some outcomes in patients with HFrEF and ID. Patients with HFrEF should be screened for ID, defined as ferritin < 100 µg/L, or ferritin 100–299 µg/L if transferrin saturation < 20%. If ID is found, IV iron should be considered, although causes of ID other than HF must not be overlooked.

Keywords: Iron deficiency, IV iron, Iron replacement, Ferrous carboxymaltose, Iron sucrose, Heart failure, Heart failure with reduced ejection fraction

Background

Unquestionably, heart failure (HF) is a major global challenge with an estimated prevalence of 3–20 cases/1000 population [1]. This increases substantially to more than 100 cases/1000 population in those aged 65 and over, and is the leading cause of hospitalisation in this age group [1, 2]. This carries significant health and economic ramifications despite numerous advances in HF management, with patients limited by worsening symptoms, exercise intolerance, and an increased risk of recurrent hospitalisation and mortality [3–5]. Moreover, approximately 50% of patients with HF have concurrent iron deficiency (ID) with or without anaemia [3, 6–8]. With such high prevalence, further studies are being conducted to determine whether targeting ID can improve HF outcomes. This review summarises normal iron homeostasis, the pathophysiology and consequences of ID in HF, and current evidence surrounding iron replacement, before discussing guideline recommendations for iron replacement therapy in patients with HF.
Iron functions and homeostasis

Iron plays a critical role within various cell systems thanks to its ability to readily undergo redox cycling between its two primary oxidative states, ferric (Fe$^{3+}$) and ferrous (Fe$^{2+}$) iron [9–11]. Indeed, iron is an important cofactor for various enzymes, acting as a catalyst for important biochemical reactions during oxygen uptake, transport, storage and oxidative metabolism [11, 12].

Most notably, iron is an obligate component of haemoglobin (Hb) allowing it to transport oxygen around the body [13]. Additionally, iron is a key component of mitochondria, necessary for energy production [6–12]. Given the significant role of iron within every mammalian cell, it becomes apparent why treating ID might be beneficial, especially given its high prevalence amongst heart failure patients.

Due to the absence of a physiological mechanism to excrete excess iron in mammals, iron homeostasis is regulated by a combination of iron absorption in the duodenum and proximal jejunum, illustrated in Fig. 1; accompanied by iron release from macrophages of the reticuloendothelial system (RES) via a delicate interaction between the hormone hepcidin and the transmembrane protein ferroportin [8, 11, 12]. Iron can either exist intracellularly in its ferrous form (Fe$^{2+}$) where it is stored as ferritin or haemosiderin; or extracellularly in its ferric form (Fe$^{3+}$) where it circulates bound to transferrin. Ferroportin is the key transmembrane protein controlling the distribution of iron by exporting the iron stored within enterocytes and RES macrophages into circulating plasma, increasing transferrin saturation (TSAT). Conversely, hepcidin is a negative regulator of iron release by binding to ferroportin and degrading it, reducing dietary iron absorption by enterocytes and iron release from RES macrophages, ultimately reducing iron levels. The interaction between hepcidin and ferroportin is the single most important regulator of total body iron [8–11].

It must be noted that total body iron exists within a narrow therapeutic window, and that iron deficiency, or iron overload (such as in haemochromatosis) can be detrimental. Although the average western diet contains 15-20 mg/day, a single human requires only 1-2 mg of iron daily to compensate for the daily loss via uncontrollable mechanisms, most notably enterocyte death in both sexes, and blood loss secondary to menstruation in females. Normally, total body iron stores are approximately 4 g, with 75% (3 g) utilised by erythroblasts to synthesise haemoglobin, emphasising iron’s critical role in oxygen transportation [8, 14, 15].

Definitions of iron deficiency

Iron deficiency is recognised as the most common nutritional deficiency worldwide, affecting one-third of the global population [6, 8]. Iron deficiency can be classified as absolute or functional. Absolute iron deficiency is defined as serum ferritin < 100 μg/L and refers to decreased total body stores mainly secondary to gastrointestinal blood loss, impaired gastrointestinal absorption, or poor appetite or nutrition [16, 17]. Conversely,
functional iron deficiency is defined as serum ferritin 100-299 μg/L, with transferrin saturation <20%. Unlike absolute ID, functional ID refers to normal or elevated total body iron stores which are theoretically capable of meeting body demand, but are unavailable for incorporation into erythroid precursors since they cannot be exported from the intracellular compartment [6, 16, 17]. The latter is typically seen in anaemia of chronic disease due to elevated hepcidin levels, inhibiting the ability of ferroportin to export intracellular iron stores, thereby resulting in reduced iron utilisation in important cellular processes including erythropoiesis [16–18].

Risk factors for ID in heart failure include elevated levels of N-terminal pro–B-type natriuretic peptide (NT-proBNP) and C-reactive protein, female sex, and advanced disease [8]. It is important to emphasise that many HF patients develop ID without being anaemic, hence screening for ID is crucial, even in the presence of normal Hb values [11]. This is commonly via measurement of serum ferritin and TSAT. However, serum ferritin is an acute-phase reactant that can be elevated during periods of inflammation, and values must be interpreted in the context of the patient’s clinical condition. Bone marrow aspiration with Prussian blue staining is gold standard for defining ID, but is understandably invasive and expensive. The current ID definition relies on ferritin levels <100 μg/L, or 100–300 μg/L with TSAT <20% and carries a sensitivity of 82% and specificity of 72% for true ID. However, one study noted that a definition based on a single parameter of TSAT ≤19.8% or serum iron ≤13 μmol/L better correlated with absolute or functional ID (sensitivity 94% for both, specificity 84% and 88% respectively; p < 0.05). Additionally, TSAT ≤19.8% and serum iron ≤13 μmol/L (and not ferritin) were independent predictors of mortality in HF patients, providing prognostic values [19, 20].

Pathophysiology and consequences of iron deficiency in heart failure

Regardless of anaemia, iron deficiency plays a key role in heart failure since cardiac myocytes have high metabolic activity, making them particularly vulnerable to decreased iron levels. A small study noted a reduction in intracellular iron stores within cardiomyocytes of explanted failing hearts compared to normal myocardium (0.49 ± 0.07 μg/g vs. 0.58 ± 0.09 μg/g, p < 0.05). This was supported by a 68% reduction in transferrin receptor 1 (Tfr1) mRNA expression in the cardiomyocytes of the failing heart compared to the nonfailing heart (p < 0.05). Given the crucial role of the transferrin receptor as the major uptake pathway for iron into myocardium, its downregulation in heart failure partly explains why cardiac iron stores were reduced. This likely occurs in response to increased levels of catecholamines and aldosterone, both of which are commonly seen in HF [6, 21].

The prevalence of intracellular ID in human cardiomyocytes in patients with advanced heart failure was further studied in left ventricular samples obtained from 91 consecutive HF patients undergoing transplantation and 38 HF-free organ donors (used as healthy controls) [22]. Myocardial iron content was lower in HF compared with controls (156 ± 41 vs. 200 ± 38 μg·g⁻¹ dry weight, P < 0.001), and ID was independent of anaemia. Cardiomyocyte ID was associated with reduced mitochondrial function, especially diminished citric acid cycle enzyme activity, and decreased expression of enzymes protecting against oxidative stress. The potential consequences of intracellular ID was also studied in human embryonic stem cell-derived cardiomyocytes by Hoes et al. These investigators demonstrated that chemically induced ID directly impaired mitochondrial respiration, with a reduction in cellular ATP levels by 74% (p < 0.0001). ID also reduced contractile force and the maximum velocities during both systole and diastole. These effects were reversible following restoration of intracellular iron levels [23].

The pathophysiology underlying ID in HF is multifactorial, with hepcidin recognised as an important contributor. Normally, during times of absolute ID, hepcidin is down-regulated to increase the ferroportin-mediated processes of iron absorption by enterocytes and iron release by RES macrophages [11, 17]. However, chronic inflammatory states such as heart failure trigger prolonged release of inflammatory mediators that depress bone marrow function whilst concurrently stimulating hepatocytes of the liver to synthesise more hepcidin. It is this upregulation of hepcidin that inhibits the release of iron from body stores, resulting in a pattern of functional, not absolute, ID despite seemingly adequate total body iron stores. The upregulation of hepcidin partly explains why oral iron supplements are ineffective in patients with ID and HF [6, 8–11, 17].

Iron deficiency in the context of heart failure is widely recognised as an independent predictor of poorer outcomes including fatigue, reduced exercise capacity, reduced quality of life (QoL), increased hospitalisation, and increased mortality [3, 6–8, 24–27]. In a prospective observational study conducted by Jankowska et al. in 546 HF patients, ID was a strong and independent predictor of death and heart transplant, regardless of anaemia [28]. This finding was reinforced by a study of 157 HF patients by Okonko et al. in which ID was associated with a three-fold higher risk of mortality, irrespective of anaemia status [27]. Additionally, ID has been shown to be an independent predictor of exercise capacity in HF patients, with lower peak oxygen consumption (VO₂
max) compared to those without ID [11, 29]. Similarly, HF patients with ID underperform in submaximal exercise tests such as the 6-min walk test (6MWT) when compared to those without ID [16, 30]. Various studies have also reported that ID is independently associated with QoL, for example predicting a higher score with the Minnesota Living with Heart Failure Questionnaire [11, 31, 32]. Notably, it has also been demonstrated that a greater prevalence of ID appears to correlate with higher (i.e., worse) New York Heart Association functional class [7, 27, 33].

**Intravenous iron therapy in heart failure**

*IV iron in heart failure with reduced ejection fraction: evidence from randomised controlled trials*

Given the significance of iron deficiency in heart failure, numerous studies have investigated the possibilities for correcting it. As of 1st June 2021, seven RCTs comparing IV iron with placebo in patients with HF were completed, designated Toblli et al. [34], FERRIC-HF [24], FAIR-HF [35], CONFIRM-HF [36], EFFECT-HF [37], PRACTICE-ASIA-HF [38] and AFFIRM-AHF [39]. A comparison of each trial is shown in Table 1. A total of 2,164 patients were enrolled, with 1166 (53.9%) randomly allocated IV iron and 998 (46.1%) allocated to placebo. Ferric carboxymaltose (FCM) was used in five trials [35–39] and iron sucrose in the other two (IS) [24, 34].

The first RCT exploring the use of IV iron in HF patients was conducted in 2007 by Toblli et al. in 40 HF patients with iron deficiency anaemia (defined as a Hb of <12.5 g/dL in men and <11.5 g/dL in women), in addition to a LVEF of ≤35% and serum ferritin of <100 ng/ml and/or with transferrin saturation (TSAT) <20%. Half were allocated to IV iron sucrose and half allocated saline, with those given iron demonstrating a reduction in NT-proBNP level, improvements in LVEF, improvements in 6MWT distance and fewer hospitalisations throughout a 6 month follow-up period (0 in iron group vs 5 in control) [34]. Okonko et al. expanded upon this in 2008 with FERRIC-HF, a randomised study involving 35 patients with concurrent HF and ID, including those with and without anaemia, demonstrating improvements in exercise capacity, patient global assessment (PGA) scores, and NYHA functional class. IV iron sucrose was well tolerated, with similar adverse events (AE) profiles between both groups [24].

The first relatively large-scale, purportedly double-blind multicentre trial was published in 2009 by Anker et al. In FAIR-HF (Ferinject Assessment in patients with IRon deficiency and chronic Heart Failure trial), 459 HF participants in NYHA functional class II or III, with LVEF ≤40–45%, ID (defined as ferritin of either <100 µg/L, or between 100 and 299 µg/L if TSAT <20%) and a Hb concentration of 95–135 g/dL, were randomised in a 2:1 ratio to either IV FCM or saline and followed up for 24 weeks. True blinding was not possible because the IV iron and saline solutions differed in colour, however measures like black syringes and curtains were used to shield the solutions. Of those given IV FCM, 50% reported an improvement in the primary outcome of patient global assessment, compared to 28% of patients allocated placebo (odds ratio [OR] for improvement: 2.51; 95% confidence interval [CI]: 1.75–3.61; p<0.001). There were also statistically significant improvements in secondary outcomes, including in NYHA functional class, 6MWT distance, and QoL quantified using the Kansas City Cardiomyopathy Questionnaire. These benefits were observed regardless of anaemia status at baseline. However, there were no significant changes to all-cause mortality (3.4% in FCM vs. 5.5%, in placebo) or first hospitalisations (17.7% in FCM vs 24.8% in placebo). There was no significant difference between treatment arms with respect to AEs, suggesting IV FCM was safe for use with no unacceptable side effects [35].

A second trial, CONFIRM-HF (Ferric Carboxymaltose evaluation on performance in patients with Iron deficiency in combination with chronic Heart Failure) was published in 2015. This was also described as a double-blind, multicentre, prospective RCT and had similar objectives to FAIR-HF and obtained similarly encouraging results, although also suffered from incomplete blinding. A total of 301 ambulatory patients with a LVEF of ≤45%, NYHA functional class II or III, an elevated NT-proBNP or B-type natriuretic peptide (BNP) and ID were enrolled. Patients were randomised 1:1 to either IV FCM or placebo and followed for 52 weeks. The primary endpoint was the change in 6MWT distance from baseline to week 24. Patients receiving IV iron achieved a greater 6MWT distance than those receiving placebo (33 m±11 m more; p=0.002) at week 24. This benefit persisted at week 52 (36±11 m; p<0.001). Additionally, NYHA class, PGA scores, QoL scores and fatigue scores improved, significantly, from week 24 onwards. Moreover, the risk of hospitalisation for HF was lower in the FCM, compared to placebo, group (hazard ratio [HR] 0.39, 95% CI 0.19–0.82; p=0.009) although this finding was based on small numbers [36]. This trial reaffirmed the findings obtained from FAIR-HF, and raised the possibility that iron therapy might reduce HF hospitalisation.

More recently, the Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency (EFFECT-HF) study reinforced the positive results obtained from earlier trials. This study randomised 174 patients with HF and ID to either IV FCM or standard care, without blinding of treatment assignment. The results, published in 2017,
| Table 1 | Current published randomised controlled trials investigating intravenous iron in heart failure |
|---------|-------------------------------------------------|
| **Publication year** | **HF diagnosis** | **Number of participants** | **Randomisation and preparation** | **Blinding** | **Primary outcomes** | **Duration of follow-up** | **Dosage** | **Important inclusion criteria** | **Definition of ID** |
| Toblli et al | 2007 | HFrEF | 40 | 1:1 Iron sucrose: placebo | Double-blind | Change in NT-proBNP level and CRP | 24 weeks | IV Iron sucrose 200 mg weekly for 5 weeks | LVEF ≤ 35% NYHA II–IV Hb < 12.5 g/dL for men and < 11.5 g/dL for women | Serum ferritin < 100 ng/mL and/or transferrin saturation (TSAT) ≤ 20% |
| | 2008 | HFrEF | 35 | 2:1 Iron sucrose: placebo | Double-blind | Change in absolute pVO2 (ml/kg/min) from baseline to week 18 | 18 weeks | IV Iron sucrose 200 mg weekly until iron repletion achieved, then every 2 weeks thereafter | LVEF ≤ 45% NYHA II–III pVO2/kg ≤ 18 ml/kg/min Hb < 12.5 g/dL non-anemic group; 12.5–14.5 g/dL non-anemic group | Serum ferritin < 100 μg/L, or between 100 and 299 μg/L if TSAT < 20% |
| | 2009 | HFrEF | 459 | 2:1 FCM: placebo | Double-blind | Changes in self-reported Patient Global Assessment and NYHA class from baseline to week 24 | 24 weeks | IV FCM 200–2000 mg based on Hb and weight | LVEF ≤ 45% NYHA II–III Elevated natriuretic peptides Hb < 15 g/dL | Serum ferritin < 100 ng/mL, or between 100 and 300 ng/mL if TSAT < 20% |
| | 2014 | HFrEF | 301 | 1:1 FCM: placebo | Double-blind | Change in 6-MWT distance from baseline to week 24 | 52 weeks | IV FCM 500–2000 mg based on Hb and weight | LVEF ≤ 45% NYHA II–III Elevated natriuretic peptides Peak VO2 of 10–20 mL/kg/min | Serum ferritin < 300 ng/mL if transferrin saturation is < 20% |
| | 2017 | HFrEF | 172 | 1:1 FCM: placebo | Double-blind | Change in 6-MWT distance from baseline to week 24 | 24 weeks | IV FCM 500–1000 mg based on Hb and weight | Hospitalised for HF Hb ≤ 14 g/dL | Serum ferritin < 100 ng/mL, or between 100 and 299 ng/mL if TSAT < 20% |
| | 2018 | Acute decompensated HF | 49 | 1:1 FCM: placebo | Single-blind | Change in 6-MWT distance over 12 weeks | 12 weeks | Single dose of 1000 mg IV FCM | LVEF ≤ 50% Hospitalised for HF | Serum ferritin < 100 ng/mL, or between 100 and 299 ng/mL if TSAT < 20% |
| | 2020 | Acute decompensated HF | 1108 | 1:1 FCM: placebo | Double-blind | Composite of total HF hospitalisations and CV death up to 52 weeks after randomisation | 52 weeks | 500–1500 mg FCM based on Hb and weight | |

HF: heart failure, CV: cardiovascular, HFrEF: heart failure with reduced ejection fraction, FCM: ferrous carboxymaltose, 6-MWT: 6-min walk test, TSAT: transferrin saturation, NYHA: New York Heart Association, LVEF: left ventricular ejection fraction, NT-proBNP: N-terminal prohormone of brain natriuretic peptide, Hb: haemoglobin, IV: intravenous
suggested patients receiving IV FCM maintained their baseline peak oxygen consumption (peak \(VO_2\)) after 24 weeks (least-square mean change: \(-0.16 \pm 0.387\) ml/min/kg; \(p = 0.02\)) whereas those receiving standard care saw a decline in \(VO_2\) over this period (least-square mean change: \(-1.19 \pm 0.389\) ml/min/kg). The between treatment difference was significant, providing more evidence that IV iron has a favourable effect on functional capacity, as compared to standard care [37].

**IV iron in acute decompensated heart failure: evidence from randomised controlled trials**

While the trials described above have shown benefit for the use of IV iron in patients with “ambulatory” (outpatient) chronic HFrEF, the effects of IV iron in patients with acute decompensated HF was unknown until recently. The AFFIRM-AHF trial, published in November 2020, has filled this gap in evidence. AFFIRM-AHF was purportedly a double-blind trial, but again did not have a placebo solution matching IV FCM. A total of 1108 patients with ID who were hospitalised with HF and had a LVEF < 50% were randomised 1:1 to either IV FCM or placebo with repeat dosing as needed for up to 24 weeks. Patients were followed for 52 weeks and the primary outcome was the composite of total hospitalisation for HF and cardiovascular (CV) death. This study narrowly missed its primary objective, with 293 primary events (57.2 per 100 patient-years) occurring in the treatment arm and 372 (72.5 per 100 patient-years) occurring in the control arm (rate ratio [RR] 0.79, 95% CI 0.62–1.01, \(p = 0.059\)). Moreover, there was no difference in CV death between groups (77 [14%] of 558 in FCM group vs 78 [14%] in the placebo group; HR 0.96, 95% CI 0.70–1.32, \(p = 0.81\)). The authors concluded that IV FCM was safe to administer in acute HF and reduced the risk of hospitalisation for heart failure, with no apparent effect on the risk of CV death [39].

The PRACTICE-ASIA-HF study recruited 50 South-east Asian patients hospitalised for acute decompensated HF with ID, regardless of LVEF, and randomised them on a 1:1 basis to either a single dose of IV FCM 1000 mg or a single dose of IV saline before discharge. In this very small trial, a single dose of IV FCM did improve functional capacity compared to placebo. Additionally, there was no overall difference in QoL scores between either group [38].

**Evidence from meta-analyses regarding iron therapy in heart failure**

A recently published meta-analysis in 2021 included all seven of the above RCTs. The aim was to evaluate whether IV iron affected the composite of hospitalisation for HF or CV mortality, as first events, in a total population of 2,166 patients (1168 assigned to IV iron; 998 assigned to control). IV iron reduced the composite of hospitalisation for heart failure or CV mortality significantly (OR 0.73; [95% CI 0.59–0.90]; \(p = 0.003\)) with this benefit driven by reduction in HF hospitalisation [OR 0.67; (0.54–0.85); \(p = 0.0007\)], without a significant effect on CV mortality [26].

Several other meta-analyses [40–43], including an individual patient data meta-analysis involving 504 patients and 335 controls [3] have suggested IV iron confers a significant reduction in all-cause mortality, CV hospitalisation, CV mortality, and HF hospitalisation in ambulatory patients with HFrEF and ID. IV iron was also associated with significant improvements in QoL as measured by various questionnaires, NYHA functional class and 6MWT distance.

**Oral iron therapy in heart failure**

Oral iron therapy, most commonly in the form of ferrous sulphate or ferrous fumarate, appear a low-cost, convenient alternative to IV iron. However, there is currently no evidence supporting their use in HFrEF, with Gregory et al. conducting a large trial titled IRONOUT HF exploring the impact of high-dose oral iron on exercise capacity (defined as a change in peak oxygen consumption, \(VO_2\) over 16 weeks in a randomised study with 225 participants. The study noted that high-dose oral iron had no effect on exercise capacity at 16 weeks compared to placebo (the primary objective), nor was there a significant difference in 6MWT distance, NT-proBNP levels, or Kansas City Cardiomyopathy Questionnaire between treatment arms. The authors concluded that “these results do not support use of oral iron supplementation in patients with HFrEF” [6].

Additionally, oral iron preparations have a high incidence of gastrointestinal side effects which may lead to poor compliance. Other disadvantages include poor absorption in the gastrointestinal tract secondary to intestinal oedema, poor diet, or coeliac disease for example. Moreover, upregulation of hepcidin, as seen in HF, ultimately reduces dietary iron absorption through mechanisms discussed earlier. As a result, only IV iron therapy is currently recommended [44, 45].

**Current guideline recommendations**

With such promising evidence favouring the use of IV FCM in HFrEF, several guideline groups have recommended the consideration of IV iron in patients with concomitant HFrEF and ID, as seen in Table 2. In 2016, the European Society of Cardiology (ESC) released updated guidelines with a class IIa (level of evidence A) recommendation to consider IV ferrous carboxymaltose in iron-deficient patients with symptomatic HFrEF.
The evidence favouring iron replacement in acute decompensated HF is currently limited and less favourable, along with inadequate evidence for iron therapy in heart failure with preserved ejection fraction (HFpEF). IV iron appears to provide no benefit regarding CV mortality. Current guidelines recommend consideration of IV iron in those with concomitant HF and ID, and this is likely to expand once current ongoing trials provide further evidence regarding the potentially significant role of IV iron in patients with ID and HF.

Whilst IV iron therapy appears a promising addition to the arsenal of therapies for HF patients, before widespread adoption of IV iron in HF can occur several key questions must be answered. This includes the safety of routine, long-term use of IV iron in HFrEF; the efficacy of iron replacement therapy for HFpEF; whether long-term IV iron confers a benefit regarding mortality; and whether alternative iron preparations aside from FCM can provide any benefit. Moreover, many of these studies excluded patients with Hb values greater than 15 g/dL, hence the efficacy and safety of IV iron is unknown in these patients. There are currently four major ongoing trials which are attempting to answer many of the aforementioned questions, including FAIR-HFpEF exploring clinical outcomes for IV iron in HFpEF [50], IRONMAN exploring the use of iron (III) isomaltoside as an alternative to ferric carboxymaltose in HFrEF and ID [51], and FAIR-HF2 [52] and HEART-FID [53] exploring the long-term clinical effects of IV FCM in HFrEF. Table 3 contains more information regarding each trial. Positive results from these major studies would likely motivate stronger guideline recommendations regarding IV iron therapy in routine practice.

IV iron was considered safe to use, with the above-mentioned studies all reporting similar side-effect profiles between treatment and control arms. No unacceptable side-effect or adverse-event profiles were observed with ferric carboxymaltose or iron sucrose. This concurs with a meta-analysis which reported IV iron was not associated with increased risk of serious AEs, and actually noted a reduction in serious AEs in HF patients (RR, 0.45; 95% CI, 0.29–0.70; I(2) = 0%) [54].

Lastly, the beneficial impact of IV iron in HFrEF was independent of baseline haemoglobin levels, hence patients with HF in the absence of anaemia should still have ferritin and TSAT measurements taken for consideration of iron therapy. The hypothesised reason behind this is because ID results in impaired mitochondrial adenosine triphosphate (ATP) synthesis long before it impacts haemopoiesis to levels detectable on a

| Guideline group                                                                 | Year of publication | Recommendation                                                                 | Class/level of evidence                                      |
|--------------------------------------------------------------------------------|---------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------|
| European Society of Cardiology [44]                                             | 2016                | IV ferrous carboxymaltose should be considered in symptomatic patients with HFrEF and ID (ferritin < 100 µg/L, or ferritin 100–299 µg/L if TSAT < 20%) | Ila (weight of evidence is in favour of usefulness)/level A |
| American Heart Association/American College of Cardiology [47]                  | 2016                | In HF patients with NYHA class II and III and ID (ferritin < 100 ng/mL, or 100–300 ng/mL if TSAT < 20%), IV iron may be reasonable to improve functional status and quality of life | Ib (weak strength of recommendation)/ level B-R               |
| Scottish Intercollegiate Guidelines Network [46]                                | 2017                | HFrEF patients with either NYHA class III and LVEF ≤ 45%, or NYHA class II and LVEF ≤ 40%, along with haemoglobin 9.5–13.5 g/dL should be considered for IV iron | 1++ (high-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias) |
| National Institute for Health and Care Excellence [48]                          | 2018                | No recommendation                                                              |                                                              |

HF heart failure, HFrEF heart failure with reduced ejection fraction, IV intravenous, ID iron deficiency, TSAT transferrin saturation, NYHA New York Heart Association, LVEF left ventricular ejection fraction, RCT randomised controlled trial

Table 2 Current guideline recommendations regarding the use of intravenous iron in heart failure
| ClinicalTrials.gov identifier | HF diagnosis | Number of participants | Randomisation and preparation | Blinding | Primary Outcomes | Duration | Important inclusion criteria | Definition of ID | Dosage |
|------------------------------|--------------|------------------------|------------------------------|----------|-----------------|----------|----------------------------|-----------------|--------|
| FAIR-HFpEF [50]              | HFrEF        | 1300                   | 1:1 FCM: placebo             | Double-blind | Change in 6-MWT distance from baseline to week 24 | 1 year   | HFrEF with LVEF ≥ 45% NYHA class II or III Either hospitalised for HF within 12 months or raised NT-proBNP Serum Hb 9.5–14 g/dL and ≤ 14.0 g/dL Serum ferritin < 100 ng/mL, or ferritin 100–299 plus TSAT < 20% 500–2000 mg FCM according to Hb and weight | Serum ferritin < 100 ng/mL, or ferritin 100–299 plus TSAT < 20% 1000–2000 mg FCM according to Hb and weight | |
| FAIR-HF2 [52]                | HFpEF        | 1200                   | 1:1 FCM: placebo             | Double-blind | Combined rate of recurrent hospitalisations for HF and of CV death from baseline to at least 12 months | Event-driven; min. 1 year | Chronic heart failure for at least 12 months Serum Hb 9.5–14 g/dL | Serum ferritin < 100 ng/mL, or serum ferritin 100–299 ng/mL with TSAT < 20% 1000–2000 mg FCM according to Hb and weight | |
| IRONMAN [51]                 | HFrEF        | 1300                   | 1:1 Iron (III) isomaltoside: placebo | Open label | CV mortality or hospitalisation for worsening HF for a minimum of 6 months after last patient recruited | Min. 2.5 years (average 3 years per participant) | LVEF < 45% NYHA class II–IV Current or recent (within 6 months) hospitalisation for HF Raised NT-proBNP | TSAT < 20% and/or ferritin < 100 ug/L Ferritin < 100 ng/mL or 100 to 300 ng/mL with TSAT < 20% Up to 750–1500 mg FCM according to Hb and body weight | |
| HEART-FID [53]               | HFpEF        | 3014                   | 1:1 FCM: placebo             | Double-blind | Incidence of death and incidence of hospitalisation for HF at 1 year Change in 6-MWT distance from baseline to 6 months | Event driven; min 1 year | LVEF ≤ 40% NYHA II–IV Hb > 9.0 g/dL and < 13.5 g/dL (females) or < 15.0 g/dL (males) Either hospitalised for HF within 12 months or elevated NT-proBNP | |

HF: heart failure, CV: cardiovascular, HFrEF: heart failure with reduced ejection fraction, HFpEF: heart failure with preserved ejection fraction, FCM: ferrous carboxymaltose, 6-MWT: 6-min walk test, TSAT: transferrin saturation, NYHA: New York Heart Association, LVEF: left ventricular ejection fraction, NT-proBNP: N-terminal prohormone of brain natriuretic peptide, Hb: haemoglobin, min: minimum
blood film. There is debate regarding whether the current definition of ID is optimal, and that using TSAT alone might give a better indication of true ID, because of ferritin's role as an acute phase reactant [20, 49]. Additionally, a TSAT < 19.8% was shown to provide prognostic benefit and independently correlate with greater mortality [20]. This is significant because the administration of iron therapy to non-iron deficient patients is unlikely to provide benefit.

A major limitation of the studies discussed in this review was blinding. Because of IV iron's characteristic dark-brown colour, the double-blinded studies would have been unable to achieve true blinding [24, 34–36, 39]. To mitigate this, black syringes were used along with curtains to prevent patients or healthcare professionals from deducing which infusion was connected. Using a solution of similar colour would have proven more reputable. Furthermore, many of the trials had small patient populations (< 500) and short follow-up durations. Whilst ongoing trials have not addressed the issue of blinding (all utilising normal saline, aside from IRONMAN which is open-label), three of the four have recruited > 1200 participants, and all have a minimum follow-up duration of 1 year, with IRONMAN 2.5–3 years. Another limitation involves the lack of objective radiological evidence, such as echocardiography, surrounding the effects of iron replacement therapy on myocardium. Such a trial may reveal the extent of benefit (or lack thereof) of IV iron in heart failure.

**Abbreviations**

HF: Heart failure; ID: Iron deficiency; IV: Intravenous; HfFe: Heart failure with reduced ejection fraction; NYHA: New York Heart Association; 6MWT: 6-Minute walk test; HfFeF: Heart failure with preserved ejection fraction; Hb: Haemoglobin; RES: Reticuloendothelial system; TSAT: Transferrin saturation; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; Tlr1: Transferrin receptor 1; QoL: Quality of life; FCM: Ferrous carboxymaltose; IS: Iron sucrose; PGA: N-terminal prohormone of brain natriuretic peptide; Tfr1: Transferrin receptor; CV: Cardiovascular; ESC: European Society of Cardiology; SIGN: Scottish Intercollegiate Guidelines Network; ACC: American College of Cardiology; AHA: American Heart Association; ATP: Adenosine triphosphate; FERRIC-HF: Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency; FAIR-HF: Ferrinject assessment in patients with Iron deficiency and chronic heart failure trial; CONFIRM-HF: Ferric Carboxymaltose evaluation on Performance in patients with Iron deficiency in conjunction with chronic heart failure; EFFECT-HF: The effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure; PRACTICE-ASIA-HF: Single-dose intravenous iron in Southeast Asian heart failure patients: a pilot randomized placebo-controlled study; AFFIRM-AHF: A randomised, double-blind placebo controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron deficient patients admitted for acute heart failure.

**Acknowledgements**

I would like to extend my gratitude to Professor John McMurray who supervised the project and provided consistent support throughout.
50. Doehner W, von Haeling S, Ebner N (2017, August 1 – 2021, July). Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction (FAIR-HFpEF). Identifier NCT03074591. https://clinicaltrials.gov/ct2/show/study/NCT03074591

51. Karla P, Thomson E (2016, August – 2022, March). Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency: IRONMAN (IRONMAN). Identifier NCT02642562. https://clinicaltrials.gov/ct2/show/study/NCT02642562

52. Karakas M, Anker S (2017, February 7 – 2021, December). Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality (FAIR-HF2). Identifier NCT03036462. https://clinicaltrials.gov/ct2/show/NCT03036462

53. Mentz RJ, Ambrosy AP, Ezekowitz JA et al (2021) Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: rationale and design. Circ Heart Fail 14(5):e008100. https://doi.org/10.1161/CIRCHEARTFAILURE.120.008100

54. Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A (2015) The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 90(1):12–23. https://doi.org/10.1016/j.mayocp.2014.10.007

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.